GRM5 and cancer: Therefore, MMG22, a dual-acting MOR agonist and mGluR5 antagonist, has significant anti-hyperalgesic effects, especially in cancer pain, inflammatory pain and neuropathic pain (Akgün et al., 2013; Shueb et al., 2019; Speltz et al., 2020).